Acromegaly Update

Acromegaly Update

By Ethan WeissScienceLife Sciences
Download on the App Store

Acromegaly Update episodes

  • Acromegaly Update — Monday August 31, 2026
    It's a quiet week for acromegaly-specific research — no top-tier trials, just a handful of diagnostic and mechanistic papers — while rare disease industry news brought two new FDA approvals (Priovant's Lisraya for dermatomyositis and Takeda/Protagonist's Mimrylo for polycythemia vera) that show regulators keep clearing novel mechanisms for small patient populations.
    7 min
  • Acromegaly Update — Monday August 24, 2026
    It was a quiet week for acromegaly-specific research — three observational studies refined how we monitor and support patients rather than changing treatment — while the wider rare disease industry saw two major FDA approvals and two sizable M&A deals land within days of each other.
    7 min
  • Acromegaly Update — Monday August 17, 2026
    It's an unusually rich week for acromegaly research — five new papers spanning a first-in-human antagonist trial and two large Swedish outcomes studies — while the rare disease industry saw a $1.3B rare-epilepsy buyout, a bankruptcy-auction gene therapy pickup, and a safety scare over a newly approved Prader-Willi drug.
    7 min
  • Acromegaly Update — Monday August 10, 2026
    It's a quiet week for acromegaly-specific trial data — the research side leans mechanistic and clinical-management, headlined by a novel long-acting GH receptor antagonist — while rare disease industry news brought a fresh Phase 2 win for Silence Therapeutics, an $800M Stargardt disease acquisition, a CRISPR safety insight from Intellia, and a Washington fight over whether orphan drugs get carved out of Medicare price pilots.
    7 min
  • Acromegaly Update — Monday August 3, 2026
    It's a quiet week for acromegaly-specific research — no trials, just incremental papers on AI-assisted detection, surgical outcomes, and pediatric gigantism — while the broader rare disease industry saw a gene-editing "gold rush" for a liver/lung disorder, a financing bet against two bigger rivals in Angelman syndrome, and a pulmonary hypertension partnership fall apart after a near-miss trial.
    8 min
  • Acromegaly Update — Monday July 27, 2026
    A trio of new Pituitary papers built out the real-world case for oral paltusotine in controlled acromegaly, while on the industry side a small rare-disease repurposing startup inked a licensing deal and orphan drugmakers pushed back on Medicare price-pilot exposure.
    7 min
  • Acromegaly Update — Monday July 20, 2026
    A quiet week for acromegaly research was anchored by a strong AI-diagnosis paper in JCEM, while rare disease headlines swung between a startup's ultrasound gene-therapy bombshell and a somber earnings-style readout on a rare endocrine disorder.
    7 min
  • Acromegaly Update — Monday July 13, 2026
    It was a quiet week for new acromegaly research, but the rare disease industry delivered its biggest story of the year — Vertex's $10 billion acquisition of Crinetics Pharmaceuticals, maker of the acromegaly drug Palsonify, directly linking this week's two segments.
    5 min
  • Acromegaly Update — Monday July 6, 2026
    It's a thin week for acromegaly-specific research — just one mechanistic study on tumor biology — but rare disease dealmaking was busy, headlined by Ipsen's ~$800M bet on a kidney-transplant antiviral and an FDA age expansion for Vertex's CRISPR therapy Casgevy.
    8 min
  • Acromegaly Update — Monday June 29, 2026
    Paltusotine's four-year open-label data confirm durable oral control of acromegaly in patients switched from injections, while the rare disease industry absorbs a landmark Sangamo bankruptcy, a well-funded gene-editing entrant in AATD, and a new build-to-buy cardiomyopathy venture from Merck KGaA.
    7 min

About Acromegaly Update

From the publisher's feed

Weekly digest of new research on acromegaly — trials, therapies, and clinical updates.